Elanco Q4 2020 Earnings Report
Key Takeaways
Elanco Animal Health reported Q4 2020 results, which included the Bayer Animal Health business acquired on August 1, 2020. Revenue reached $1,139.7 million, driven by strong performance in U.S. Pet Health, U.S. Farm Animal, and China swine. Adjusted EPS was at the high end of the guidance range, and the company increased its full-year 2021 guidance.
Elanco's fourth-quarter revenue surpassed expectations, driven by U.S. Pet Health, U.S. Farm Animal, and China swine performance.
Adjusted EPS met the high end of guidance, supported by productivity initiatives.
Innovation is progressing with eight product launches planned for 2021.
The company is executing synergies from the Bayer Animal Health acquisition.
Elanco
Elanco
Forward Guidance
Elanco is raising full year 2021 guidance for revenue, adjusted EBITDA, and adjusted earnings per share. Elanco is also raising full year 2021 guidance for reported EPS . Additionally, Elanco is introducing guidance for the first quarter of 2021, to provide further support to the cadence of expectations throughout the full year.